NexMed awaits completion of new manufacturing facility

NexMed Inc. (Robbinsville, NJ) has signed an agreement to purchase a 31,500-square-foot manufacturing facility currently under construction in East Windsor, New Jersey. The facility will serve as NexMed's base of operations for the manufacture and quality control of its Alprox-TD cream treatment for male erectile dysfunction (ED) and Femprox cream treatment for female sexual arousal disorder (FSAD). The company expects the facility to be in operation in late 2000.

"Following an extensive search throughout New Jersey and eastern Pennsylvania, we selected the East Windsor site because of its proximity to our headquarters in Robbinsville, its accessibility to major transportation arteries, and the availability of skilled labor in the area," Y. Joseph Mo, NexMed's president and CEO, said in a company release.

Mo added that NexMed plans to use the facility to manufacture clinical supplies for the company's planned Phase III studies on the Alprox-TD cream, pending FDA approval.

NexMed Inc. is a pharmaceutical and medical technology company with a product development pipeline of topical drug treatments based on the NexACT acute transdermal delivery technology. Its two lead NexACT products under development are the Alprox-TD cream treatment for ED and the Femprox cream treatment for FSAD.

For more information: NexMed Inc., 350 Corporate Blvd., Robbinsville, NJ 08691. Tel: 609-208-9688. Fax: 609-208-1868.

Edited by Jim Pomager
Assistant Editor, Pharmaceutical Online